Evidence map›Paper›PMID 19633051›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2010

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

G Viale, A Giobbie-Hurder, B A Gusterson, E Maiorano, M G Mastropasqua, A Sonzogni, E Mallon, M Colleoni, M Castiglione-Gertsch, M M Regan and 9 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 7 countries.

G VialeDivision of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.viale@ieo.it.
A Giobbie-HurderInternational Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA.
B A GustersonDivision of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow, UK.
E MaioranoDepartment of Pathological Anatomy, University of Bari, Bari, Italy.
M G MastropasquaDivision of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy.
A SonzogniDivision of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy.
E MallonDivision of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow, UK.
M ColleoniDepartment of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy.
M Castiglione-GertschInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
M M ReganInternational Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA.
K N PriceInternational Breast Cancer Study Group, Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA.
R W BrownMelbourne Pathology, Collingwood, Victoria, Australia.
R GolouhDepartment of Pathology, Institute of Oncology, Ljubljana, Slovenia.
D CrivellariDepartment of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
P KarlssonDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
C ÖhlschlegelSwiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
R D GelberInternational Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard School of Public Health, Boston, MA, USA.
A GoldhirschEuropean Institute of Oncology, Milan, Italy; Department of Medicine, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
A S CoatesScientific Committee, International Breast Cancer Study Group, Bern, Switzerland; School of Public Health, University of Sydney, Sydney, Australia.
Dana-Farber Cancer Institute · USEuropean Institute of Oncology · ITInternational Breast Cancer Study Group · CHUniversity of Glasgow · GBUniversity of Milan · ITCentro di Riferimento Oncologico · ITDana-Farber/Harvard Cancer Center · USFrontier Science & Technology Research Foundation · USInstitute of Oncology Ljubljana · SIInstitute of Oncology Research · CHSahlgrenska University Hospital · SESwiss Group For Clinical Cancer Research · CHUniversity of Bari Aldo Moro · IT

Funding

IBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5M
NCI NIH HHS CA-75362NCI NIH HHS U24 CA075362
6 · The paper itself

Abstract

backgroundPeritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. PATIENTS AND

methodsPatients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin-eosin-stained slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years).

resultsPVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy.

conclusionAdequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative disease, while PVI may identify patients who will benefit particularly from adjuvant therapy.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDisease ProgressionFemaleFluorouracilGoserelinHumansMenopauseMethotrexateMiddle AgedAntineoplastic Agents, HormonalCyclophosphamideFluorouracilGoserelinMethotrexate

Identifiers

PMID19633051
PMCPMC2813305
OpenAlexW2118697447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.